Matt Hewitt

Stock Analyst at Craig-Hallum

(0.77)
# 2362
Out of 5,370 analysts
55
Total ratings
44.44%
Success rate
0.08%
Average return
19 Stocks
Name Action PT Current % Upside Ratings Updated
SLP Simulations Plus
Maintains: Buy
45 36
18.96 89.87% 8 Jun 13, 2025
CSBR Champions Oncology
Maintains: Strong Buy
8 12
7.75 54.84% 4 Mar 12, 2025
BLFS BioLife Solns
Maintains: Strong Buy
30 32
22.26 43.76% 4 Nov 13, 2024
OMCL Omnicell
Maintains: Strong Buy
45 64
29.17 119.4% 5 Oct 31, 2024
LGND Ligand Pharmaceutica...
Maintains: Strong Buy
135 140
114.78 21.97% 3 Jul 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
25 10
2.19 356.62% 3 May 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
35 30
21.21 41.44% 3 May 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 2 Jan 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
23
n/a n/a 1 Jan 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
22 16
n/a n/a 4 Dec 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
7
2.23 213.9% 1 Nov 29, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
207 200
126.08 58.63% 3 Aug 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
10
1.75 471.43% 1 Apr 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
5 2
n/a n/a 2 Mar 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
3 2
n/a n/a 1 May 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
67 30
7.03 326.74% 5 Apr 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
400
1 39900% 1 Jan 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
21 30
n/a n/a 3 Jul 28, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
11
n/a n/a 1 Jul 24, 2017